Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 7/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.43 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 7/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.40 |
| ▸ | S1PR5 | Q9H228 | 5/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
| ▸ | MYLK4 | Q86YV6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670047 | 1.00 | SPHK1 (0.45) | SPHK1LTA4HSPHK2S1PR1S1PR3 | |
| SCHEMBL18921010 | 0.87 | SPHK1 (0.47) | SPHK1LTA4HSPHK2S1PR1S1PR3 | |
| SCHEMBL18921008 | 0.87 | SPHK1 (0.47) | SPHK1LTA4HSPHK2S1PR1S1PR3 | |
| SCHEMBL7033590 | 0.86 | MAPT (0.45) | LTA4HS1PR1S1PR3AAK1 | |
| SCHEMBL6286634 | 0.85 | S1PR1 (0.43) | SPHK1LTA4HSPHK2S1PR1S1PR3 | |
| SCHEMBL12155254 | 0.85 | LTA4H (0.49) | LTA4HS1PR1S1PR3 | |
| SCHEMBL7136775 | 0.84 | HPGD (0.46) | LTA4HS1PR1S1PR3AAK1 | |
| SCHEMBL22644041 | 0.84 | LTA4H (0.45) | SPHK1LTA4HSPHK2S1PR1S1PR3 | |
| SCHEMBL16784039 | 0.83 | SPHK1 (0.46) | SPHK1CYP17A1ROCK1MYLK4 | |
| SCHEMBL22457856 | 0.82 | SUV39H2 (0.46) | SPHK1SPHK2S1PR1S1PR3AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487520-B2 | Coelenterazine derivatives and methods of using same | PROMEGA CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2635583-B1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | PROMEGA CORP (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2635583-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | Promega Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| CN-103180324-A | Coelenterazine derivatives and methods of using same | PROMEGA CORP | 2013-06-26 | — | — | CN | disclosed |
| WO-2012061477-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120107849-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107849-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | SI, CNDP2, PEPD | SPHK1 3101/4885LTA4H 412/4885SPHK2 3049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.